申请人:ETH ZURICH
公开号:US20210322404A1
公开(公告)日:2021-10-21
The present invention is directed to a compound for inhibiting (i) FGF-R kinase activity or (ii) a component of the FGFR kinase signaling pathway for use in the therapeutic or prophylactic treatment of viral infections as well as corresponding pharmaceutical compositions for use in the same treatment and related methods of treatment.